Basketball athlete receives sanction

  • Doping Violation Update

The Australian Sports Anti-Doping Authority (ASADA) today acknowledged the decision of Basketball Australia to impose a four-year ban on athlete Brian Carminati.

Mr Carminati returned an Adverse Analytical Finding from an in-competition doping control test on 22 June 2018 following a NWBL game against Adelaide Thunder in Kilsyth, Victoria.

His sample was analysed at the Australian Sports Drug Testing Laboratory, part of the National Measurement Institute, which detected the presence of Higenamine, 1,4-Dimethylpentylamine and GW1516 sulfone and GW1516 sulfoxide (metabolites of GW1516).

It was determined that on or before 22 June 2018 Mr Carminati used a Prohibited Substance/s, namely Higenamine and /or GW1516.

Athletes are warned 1,4-Dimethylpentylamine is banned in-competition only under the S6 class of Stimulants. The substance is similar in structure to 1,3-dimethylamylamine (DMAA), which can cause side effects including cerebral haemorrhage and heart attacks and has been linked to a number of deaths in Australia and overseas.

Higenamine is a S3 class Beta-2 Agonist (these types of substances allow the lungs to take in more oxygen) and is prohibited in- and out-of-competition. However, as a cardiotonic, higenamine can increase heart rate, putting an athlete at an increased risk of arrhythmias and even death.

GW1516, a S4 class Hormone and Metabolic Modulator, works by forcing skeletal muscle to use fat rather than carbohydrates as an energy source. Used by some for fat loss, in the context of athletic enhancement, GW1516 also has benefits as an endurance aid. However, it was discontinued in 2007 after it was linked to the rapid development of cancer during trials on mice.

Mr Carminati is ineligible to participate in any sports that have adopted a World Anti-Doping Code compliant anti-doping policy until 17 August 2022.